| Abstract | Twelve patients with a long-standing history of moderate to severe symptoms of tardive dyskinesia, which had remained stable for several months, participated in a 6-week trial with bromocriptine. All patients were receiving a concomitant neuroleptic medication and were treated with a low dose of bromocriptine (0.75 to 7.5 mg). Patients showed a modest overall improvement of 16.6%, with a trend for greater improvement in male patients (23.6%). Baseline prolactin levels in the female patients showed a positive correlation with age and duration of tardive dyskinesia symptomatology. Plasma prolactin levels 4 hours following administration of bromocriptine were negatively correlated with the dose of bromocriptine. There appears to be a differential sensitivity for prolactin and growth hormone response to bromocriptine at these low doses in the presence of chronic neuroleptic treatment. |
| Authors | R H Lenox, L A Weaver, B M Saran |
| Journal | Journal of clinical psychopharmacology
(J Clin Psychopharmacol)
Vol. 5
Issue 5
Pg. 286-92
(Oct 1985)
ISSN: 0271-0749 UNITED STATES |
| PMID | 4044881
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, P.H.S.)
|
| Chemical References |
- Bromocriptine
- Prolactin
- Growth Hormone
|
| Topics |
- Bromocriptine
(therapeutic use)
- Dyskinesia, Drug-Induced
(blood, drug therapy)
- Female
- Growth Hormone
(blood)
- Humans
- Male
- Prolactin
(blood)
|
